217 related articles for article (PubMed ID: 25682017)
1. Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in non-small-cell lung cancer.
Fujii A; Harada T; Iwama E; Ota K; Furuyama K; Ijichi K; Okamoto T; Okamoto I; Takayama K; Nakanishi Y
Cancer Genet; 2015 May; 208(5):271-8. PubMed ID: 25682017
[TBL] [Abstract][Full Text] [Related]
2. Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer.
He C; Zheng L; Xu Y; Liu M; Li Y; Xu J
Clin Chim Acta; 2013 Oct; 425():119-24. PubMed ID: 23886554
[TBL] [Abstract][Full Text] [Related]
3. Detection of low-level EGFR T790M mutation in lung cancer tissues.
Oh JE; An CH; Yoo NJ; Lee SH
APMIS; 2011 Jul; 119(7):403-11. PubMed ID: 21635547
[TBL] [Abstract][Full Text] [Related]
4. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.
Kosaka T; Yatabe Y; Endoh H; Yoshida K; Hida T; Tsuboi M; Tada H; Kuwano H; Mitsudomi T
Clin Cancer Res; 2006 Oct; 12(19):5764-9. PubMed ID: 17020982
[TBL] [Abstract][Full Text] [Related]
5. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
[TBL] [Abstract][Full Text] [Related]
6. T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.
Li W; Ren S; Li J; Li A; Fan L; Li X; Zhao C; He Y; Gao G; Chen X; Li S; Shi J; Zhou C; Fei K; Schmid-Bindert G
Lung Cancer; 2014 Jun; 84(3):295-300. PubMed ID: 24685306
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
Uramoto H; Yamada T; Yano S; Kondo N; Hasegawa S; Tanaka F
Anticancer Res; 2012 Sep; 32(9):3785-90. PubMed ID: 22993320
[TBL] [Abstract][Full Text] [Related]
8. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T
BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.
Sun JM; Ahn MJ; Choi YL; Ahn JS; Park K
Lung Cancer; 2013 Nov; 82(2):294-8. PubMed ID: 24035188
[TBL] [Abstract][Full Text] [Related]
10. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
[TBL] [Abstract][Full Text] [Related]
11. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.
Hata A; Katakami N; Yoshioka H; Takeshita J; Tanaka K; Nanjo S; Fujita S; Kaji R; Imai Y; Monden K; Matsumoto T; Nagata K; Otsuka K; Tachikawa R; Tomii K; Kunimasa K; Iwasaku M; Nishiyama A; Ishida T; Nishimura Y
Cancer; 2013 Dec; 119(24):4325-32. PubMed ID: 24105277
[TBL] [Abstract][Full Text] [Related]
12. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
Balak MN; Gong Y; Riely GJ; Somwar R; Li AR; Zakowski MF; Chiang A; Yang G; Ouerfelli O; Kris MG; Ladanyi M; Miller VA; Pao W
Clin Cancer Res; 2006 Nov; 12(21):6494-501. PubMed ID: 17085664
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Wu JY; Yu CJ; Chang YC; Yang CH; Shih JY; Yang PC
Clin Cancer Res; 2011 Jun; 17(11):3812-21. PubMed ID: 21531810
[TBL] [Abstract][Full Text] [Related]
14. Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.
Li XY; Wu JZ; Cao HX; Ma R; Wu JQ; Zhong YJ; Feng JF
Oncol Rep; 2013 May; 29(5):1975-82. PubMed ID: 23440266
[TBL] [Abstract][Full Text] [Related]
15. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.
Rosell R; Molina MA; Costa C; Simonetti S; Gimenez-Capitan A; Bertran-Alamillo J; Mayo C; Moran T; Mendez P; Cardenal F; Isla D; Provencio M; Cobo M; Insa A; Garcia-Campelo R; Reguart N; Majem M; Viteri S; Carcereny E; Porta R; Massuti B; Queralt C; de Aguirre I; Sanchez JM; Sanchez-Ronco M; Mate JL; Ariza A; Benlloch S; Sanchez JJ; Bivona TG; Sawyers CL; Taron M
Clin Cancer Res; 2011 Mar; 17(5):1160-8. PubMed ID: 21233402
[TBL] [Abstract][Full Text] [Related]
17. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.
Onitsuka T; Uramoto H; Nose N; Takenoyama M; Hanagiri T; Sugio K; Yasumoto K
Lung Cancer; 2010 May; 68(2):198-203. PubMed ID: 19589612
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.
Su KY; Chen HY; Li KC; Kuo ML; Yang JC; Chan WK; Ho BC; Chang GC; Shih JY; Yu SL; Yang PC
J Clin Oncol; 2012 Feb; 30(4):433-40. PubMed ID: 22215752
[TBL] [Abstract][Full Text] [Related]
20. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]